Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
- Sponsor
- Samsung Medical Center
- Study ID
- NCT01776684
- Status
- Unknown
Conditions
- EGFR Mutation Positive Non-small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
Study Details
To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.
Key Dates
- First listed
- Jan 28, 2013
- Start date
- Jun 30, 2012
- Status verified
- Jan 2013
- Primary completion
- May 31, 2014
- Completion
- May 31, 2015
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: EGFR positive armPatients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)
Primary Outcome Measure
detection of resistant gene [ Time Frame: 24 months ]
Central Contacts
- Myung-Ju Ahn, M.D., Ph.D.
- Jong-Mu Sun, M.D., Ph.D.
Related Studies
- Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerPHASE1 · Recruiting · Nuvectis Pharma, Inc. · Calverton, Maryland